ClinicalTrials.Veeva

Menu
M

Metroplex Pulmonary and Sleep Center | McKinney, TX

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Dupilumab
SAR443765
BMS-986278
INS018_055
SAR440340
Lunsekimig
AZLI
BLU-5937
Rocatinlimab
Tiotropium Bromide

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

16 of 27 total trials

A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough (CALM-1)

This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 3 study of BLU-5937 in participants with Refractory Chronic Cough (RCC).

Enrolling
Refractory Chronic Cough
Drug: BLU-5937
Drug: Placebo

The primary objective of this study is to describe the efficacy of rocatinlimab in reducing asthma exacerbations.

Enrolling
Asthma
Drug: Placebo
Drug: Rocatinlimab

ACT18018 is a multinational, randomized, double-blind, placebo-controlled, parallel-group, Phase 2 study with 3 treatment groups. The purpose of this...

Enrolling
Bronchiectasis
Drug: Placebo
Drug: Itepekimab (SAR440340)

The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in participants with Idiopathic Pulmonary Fibrosis.

Enrolling
Idiopathic Pulmonary Fibrosis
Drug: BMS-986278
Drug: BMS-986278 Placebo

The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis.

Enrolling
Progressive Pulmonary Fibrosis
Drug: BMS-986278 Placebo
Drug: BMS-986278

This is a parallel, double blind, Phase 3, 2-arm study that is designed to provide additional safety information, assess the durability of treatment...

Enrolling
Chronic Obstructive Pulmonary Disease
Drug: Placebo
Drug: Itepekimab (SAR440340)

This is a Phase 2b, global, multicenter, randomized, double-blind, placebo-controlled, parallel group, dose ranging study to assess the efficacy, saf...

Active, not recruiting
Asthma
Drug: Placebo
Drug: Lunsekimig

This study evaluates the efficacy and safety of benralizumab as an add-on therapy in uncontrolled eosinophilic asthma participants treated with mediu...

Not yet enrolling
Eosinophilic Asthma
Combination Product: Placebo for Benralizumab
Combination Product: benralizumab

This is an interventional, randomized, parallel group, treatment, Phase 3b/4, double blind, 2-arm study to assess the effect of dupilumab compared to...

Enrolling
Asthma
Drug: Placebo
Drug: Dupilumab

The goal of this clinical trial is to learn about INS018_055 in adults with Idiopathic Pulmonary Fibrosis (IPF).The primary objective is to evaluate...

Enrolling
Idiopathic Pulmonary Fibrosis (IPF)
Drug: Placebo
Drug: INS018_055

This is a pivotal Phase 2/3, double-blind, placebo-controlled study of epetraborole + OBR (Optimized Background Regimen) versus placebo + OBR in pati...

Active, not recruiting
MAC Lung Disease
Treatment Refractory MAC Lung Disease
Drug: Epetraborole
Drug: Placebo

This is a parallel-group, Phase 2, randomized, double-blind, placebo-controlled, 2-arm study for the treatment of asthma.The purpose of this study is...

Enrolling
Asthma
Drug: Short-Acting Beta Agonists (SABA)
Drug: Fluticasone/salmeterol

The goal of this clinical study is to learn more about the study drug, obeldesivir (ODV; GS-5245), and how safe and effective it is in treating nonho...

Enrolling
RSV Infection
Drug: Obeldesivir
Drug: Obeldesivir Placebo

Study RIN-PF-305 is designed to evaluate the safety and efficacy of inhaled treprostinil in subjects with progressive pulmonary fibrosis (PPF) over a...

Enrolling
Progressive Pulmonary Fibrosis
Interstitial Lung Disease
Device: Treprostinil Ultrasonic Nebulizer
Drug: Placebo

The primary objective of this study is to evaluate the safety and tolerability of oral daily administration of TTI-101 over a 12-week treatment durat...

Enrolling
Idiopathic Pulmonary Fibrosis
Drug: TTI-101
Drug: Placebo

Primary Objective:Evaluate the efficacy of itepekimab compared with placebo on the annualized rate of acute moderate-or-severe COPD exacerbations in...

Active, not recruiting
Chronic Obstructive Pulmonary Disease
Drug: Placebo
Drug: Itepekimab SAR440340

Trial sponsors

Sanofi logo
Bristol-Myers Squibb (BMS) logo
Gilead Sciences logo
I
V
A
Allergan logo
Amgen logo
AstraZeneca logo
B

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems